Intarcia is a specialty biopharma and device company focused on long-acting drug delivery via an implanted osmotic mini-pump that provides continuous, controlled release of therapeutics. The platform is designed to improve patient adherence by reducing dosing frequency for chronic diseases such as diabetes. Intarcia’s work spans formulation science, device engineering, surgical delivery approaches, and clinical development. The company partners with pharmaceutical developers to embed therapies in its proprietary delivery system, combining medical device rigor with biopharma regulatory pathways.
What Is Intarcia and What Does It Do?
Intarcia, founded in 1995, is a Boston–based (United States) drug-delivery company that develops a subcutaneous osmotic mini-pump for long-term delivery of therapeutics; the company employs 201-500 people. Its flagship approach places a small implant under the skin, where osmotic pressure drives a piston to release fitted drug volumes over months.
Intarcia’s technology targets chronic conditions where adherence is critical (e.g., diabetes, metabolic disease), seeking to improve outcomes by converting daily or weekly dosing into a long-duration, maintenance therapy.
How Much Funding Has Intarcia Raised?
1. Series J
- Amount Raised: $525M
- Date: Aug 2017
- Lead Investors: Gates Foundation (strategic grant/partnering), others
- Motivation: Late-stage clinical development and scaling manufacturing capacity.
2. Series J (Extension)
- Amount Raised: $198M
- Date: Jan 14, 2020
- Lead Investors: Institutional backers
- Motivation: Support pivotal trials and regulatory activities.
3. Series J (Earlier tranche)
- Amount Raised: $8M
- Date: Jan 17, 2018
- Lead Investors: Ascent Venture Partners, Osage Partners, NXT Ventures
- Motivation: Product engineering and clinical trial support.
Total Funding Raised: $1.89 Billion
Current Valuation: $5.5 Billion (as of Apr 2015)
Latest Funding Date: Jan 2020
Key Investors
1. Gates Foundation (Bill & Melinda Gates Foundation)
- Details: Philanthropic foundation investing in health innovations and late-stage product support.
- Investment Focus Areas: Global health, biotech, scalable delivery solutions.
- Notable Investments/Grants: Vaccine & medtech programs, global health R&D initiatives.
2. Venrock / Foresite-style Investors
- Details: Life-science and healthcare investors backing clinical-stage innovators.
- Investment Focus Areas: Drug delivery, biologics, specialty therapeutics.
Where Is Intarcia’s Headquarters?
Intarcia is headquartered in Boston, United States, providing proximity to biotech talent, clinical partners, and manufacturing networks.
What’s Next for Intarcia?
Intarcia’s next steps historically centered on completing pivotal trials, securing regulatory approvals, and establishing scalable manufacturing and commercialization partnerships to bring long-acting delivery solutions to market.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Intarcia. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
